Targeting αV-integrins decreased metastasis and increased survival in a nude rat breast cancer brain metastasis model
暂无分享,去创建一个
[1] A. Pavlick,et al. Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma , 2012, Investigational New Drugs.
[2] G. van der Pluijm,et al. Tumorigenesis and Neoplastic Progression Integrin v Expression Is Required for the Acquisition of a Metastatic Stem / Progenitor Cell Phenotype in Human Prostate Cancer , 2011 .
[3] P. Fracasso,et al. A phase 1, multicenter, open-label study of the safety of two dose levels of a human monoclonal antibody to human αv integrins, intetumumab, in combination with docetaxel and prednisone in patients with castrate-resistant metastatic prostate cancer , 2011, Investigational New Drugs.
[4] D. Schadendorf,et al. A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma , 2011, British Journal of Cancer.
[5] J. Feyen,et al. Targeting of α(v)-integrins in stem/progenitor cells and supportive microenvironment impairs bone metastasis in human prostate cancer. , 2011, Neoplasia.
[6] Wolfhard Semmler,et al. Cilengitide inhibits progression of experimental breast cancer bone metastases as imaged noninvasively using VCT, MRI and DCE‐MRI in a longitudinal in vivo study , 2011, International journal of cancer.
[7] David A. Cheresh,et al. Integrins in cancer: biological implications and therapeutic opportunities , 2010, Nature Reviews Cancer.
[8] S. Knox,et al. Cancer esearch apeutics , Targets , and Chemical Biology i – α v Integrin Monoclonal Antibody Intetumumab Enhances Efficacy of Radiation Therapy and Reduces Metastasis R uman Cancer Xenografts in Nude Rats , 2010 .
[9] P. Steeg,et al. Heterogeneous Blood–Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer , 2010, Clinical Cancer Research.
[10] B. Felding-Habermann,et al. Activation of tumor cell integrin αvβ3 controls angiogenesis and metastatic growth in the brain , 2009, Proceedings of the National Academy of Sciences.
[11] A. Bandyopadhyay,et al. Defining the Role of Integrin αvβ6 in Cancer , 2009 .
[12] D. Tarin,et al. Integrin αvβ3/c-src “Oncogenic Unit” Promotes Anchorage-independence and Tumor Progression , 2009, Nature Medicine.
[13] E. Neuwelt,et al. Cyclophosphamide enhances human tumor growth in nude rat xenografted tumor models. , 2009, Neoplasia.
[14] S. Steinberg,et al. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. , 2008, Journal of the National Cancer Institute.
[15] S. Lockett,et al. Inhibition of metastatic outgrowth from single dormant tumor cells by targeting the cytoskeleton. , 2008, Cancer research.
[16] B. Garmy-Susini,et al. Integrins in angiogenesis and lymphangiogenesis , 2008, Nature Reviews Cancer.
[17] T. Mikkelsen,et al. Cilengitide: an integrin-targeting arginine–glycine–aspartic acid peptide with promising activity for glioblastoma multiforme , 2008 .
[18] G. Thomas,et al. alpha vbeta 6 Integrin promotes the invasion of morphoeic basal cell carcinoma through stromal modulation. , 2008, Cancer research.
[19] E. Raymond,et al. Phase I and pharmacokinetic study of etaracizumab (Abegrin™), a humanized monoclonal antibody against αvβ3 integrin receptor, in patients with advanced solid tumors , 2008, Investigational New Drugs.
[20] I. Hart,et al. Integrin trafficking and its role in cancer metastasis , 2007, Cancer and Metastasis Reviews.
[21] G. Krissansen,et al. Antisense integrin αV and β3 gene therapy suppresses subcutaneously implanted hepatocellular carcinomas , 2007 .
[22] S. Steinberg,et al. Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. , 2007, Cancer research.
[23] Robert A. Beckman,et al. Phase I Evaluation of a Fully Human Anti–αv Integrin Monoclonal Antibody (CNTO 95) in Patients with Advanced Solid Tumors , 2007, Clinical Cancer Research.
[24] V. Tse,et al. Molecular events of brain metastasis. , 2007, Neurosurgical focus.
[25] P. Kiener,et al. Direct targeting of αvβ3 integrin on tumor cells with a monoclonal antibody, Abegrin™ , 2006, Molecular Cancer Therapeutics.
[26] D. Schlaepfer,et al. Integrin-regulated FAK-Src signaling in normal and cancer cells. , 2006, Current opinion in cell biology.
[27] E. Neuwelt,et al. The Chemoprotective Agent N-Acetylcysteine Blocks Cisplatin-Induced Apoptosis through Caspase Signaling Pathway , 2005, Journal of Pharmacology and Experimental Therapeutics.
[28] Wenjun Guo,et al. Integrin signalling during tumour progression , 2004, Nature Reviews Molecular Cell Biology.
[29] M. Trikha,et al. CNTO 95, a fully human monoclonal antibody that inhibits αv integrins, has antitumor and antiangiogenic activity in vivo , 2004, International journal of cancer.
[30] N. Fedarko,et al. Bone sialoprotein, matrix metalloproteinase 2, and alpha(v)beta3 integrin in osteotropic cancer cell invasion. , 2004, Journal of the National Cancer Institute.
[31] D. Stupack,et al. A Bit-role for integrins in apoptosis , 2004, Nature Cell Biology.
[32] Heather Kalish,et al. Comparison of Transfection Agents in Forming Complexes with Ferumoxides, Cell Labeling Efficiency, and Cellular Viability , 2004, Molecular imaging.
[33] David A. Cheresh,et al. Role of integrins in cell invasion and migration , 2002, Nature Reviews Cancer.
[34] Hiroyuki Shimada,et al. Preferential Susceptibility of Brain Tumors to the Antiangiogenic Effects of an &agr;v Integrin Antagonist , 2001, Neurosurgery.
[35] D. Cheresh,et al. Role of alpha v integrins during angiogenesis. , 2000, Cancer journal.
[36] Xin Li,et al. Dynamic magnetic resonance imaging assessment of vascular targeting agent effects in rat intracerebral tumor models. , 2011, Neuro-oncology.
[37] A. Bandyopadhyay,et al. Defining the role of integrin alphavbeta6 in cancer. , 2009, Current drug targets.
[38] E. Raymond,et al. Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors. , 2008, Investigational new drugs.
[39] G. Krissansen,et al. Antisense integrin alphaV and beta3 gene therapy suppresses subcutaneously implanted hepatocellular carcinomas. , 2007, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[40] F. McCabe,et al. CNTO 95, a fully human anti αv integrin antibody, inhibits cell signaling, migration, invasion, and spontaneous metastasis of human breast cancer cells , 2007, Clinical & Experimental Metastasis.
[41] R. Weil,et al. Brain metastases of breast cancer. , 2006, Breast disease.
[42] D. Stupack,et al. Integrins and angiogenesis. , 2004, Current topics in developmental biology.
[43] N. Fedarko,et al. Bone sialoprotein, matrix metalloproteinase 2, and alpha(v)beta3 integrin in osteotropic cancer cell invasion. , 2004, Journal of the National Cancer Institute.
[44] K. Arihiro,et al. Significance of alpha 9 beta 1 and alpha v beta 6 integrin expression in breast carcinoma. , 2000, Breast cancer.
[45] K. Arihiro,et al. Significance of α9β1 and αvβ6 integrin expression in breast carcinoma , 2000 .